| Long-circulating and target-specific nanoparticles: theory to practice SM Moghimi, AC Hunter, JC Murray Pharmacological reviews 53 (2), 283-318, 2001 | 4796 | 2001 |
| Nanomedicine: current status and future prospects SM Moghimi, AC Hunter, JC Murray The FASEB journal 19 (3), 311-330, 2005 | 2688 | 2005 |
| A two-stage poly (ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy SM Moghimi, P Symonds, JC Murray, AC Hunter, G Debska, A Szewczyk Molecular therapy 11 (6), 990-995, 2005 | 1279 | 2005 |
| Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective SM Moghimi, AC Hunter, TL Andresen Annual review of pharmacology and toxicology 52 (1), 481-503, 2012 | 606 | 2012 |
| Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity AC Hunter Advanced drug delivery reviews 58 (14), 1523-1531, 2006 | 528 | 2006 |
| Poloxamers and poloxamines in nanoparticle engineering and experimental medicine SM Moghimi, AC Hunter Trends in biotechnology 18 (10), 412-420, 2000 | 513 | 2000 |
| Agricultural robotics: the future of robotic agriculture T Duckett, S Pearson, S Blackmore, B Grieve, WH Chen, G Cielniak, ... arXiv preprint arXiv:1806.06762, 2018 | 331 | 2018 |
| Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere− serum interface: implications for stealth nanoparticle engineering I Hamad, O Al-Hanbali, AC Hunter, KJ Rutt, TL Andresen, SM Moghimi ACS nano 4 (11), 6629-6638, 2010 | 307 | 2010 |
| Poly (ethylene glycol) s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process I Hamad, AC Hunter, J Szebeni, SM Moghimi Molecular immunology 46 (2), 225-232, 2008 | 301 | 2008 |
| Material properties in complement activation SM Moghimi, AJ Andersen, D Ahmadvand, PP Wibroe, TL Andresen, ... Advanced drug delivery reviews 63 (12), 1000-1007, 2011 | 282 | 2011 |
| Polycation cytotoxicity: a delicate matter for nucleic acid therapy—focus on polyethylenimine L Parhamifar, AK Larsen, AC Hunter, TL Andresen, SM Moghimi Soft Matter 6 (17), 4001-4009, 2010 | 255 | 2010 |
| Capture of stealth nanoparticles by the body’s defences SM Moghimi, C Hunter Critical Reviews™ in Therapeutic Drug Carrier Systems 18 (6), 2001 | 214 | 2001 |
| Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups SM Moghimi, AC Hunter Pharmaceutical research 18, 1-8, 2001 | 199 | 2001 |
| Complement activation cascade triggered by PEG–PL engineered nanomedicines and carbon nanotubes: The challenges ahead SM Moghimi, AJ Andersen, SH Hashemi, B Lettiero, D Ahmadvand, ... Journal of controlled release 146 (2), 175-181, 2010 | 191 | 2010 |
| PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance JK Gbadamosi, AC Hunter, SM Moghimi FEBS letters 532 (3), 338-344, 2002 | 190 | 2002 |
| Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes PP Wibroe, AC Anselmo, PH Nilsson, A Sarode, V Gupta, R Urbanics, ... Nature nanotechnology 12 (6), 589-594, 2017 | 185 | 2017 |
| Causative factors behind poloxamer 188 (Pluronic F68, Flocor™)-induced complement activation in human sera: A protective role against poloxamer-mediated complement activation … SM Moghimi, AC Hunter, CM Dadswell, S Savay, CR Alving, J Szebeni Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1689 (2), 103-113, 2004 | 158 | 2004 |
| Cationic carriers of genetic material and cell death: a mitochondrial tale AC Hunter, SM Moghimi Biochimica et Biophysica Acta (BBA)-Bioenergetics 1797 (6-7), 1203-1209, 2010 | 153 | 2010 |
| Low and high molecular weight poly (l-lysine) s/poly (l-lysine)–DNA complexes initiate mitochondrial-mediated apoptosis differently P Symonds, JC Murray, AC Hunter, G Debska, A Szewczyk, SM Moghimi FEBS letters 579 (27), 6191-6198, 2005 | 152 | 2005 |
| Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective AC Hunter, J Elsom, PP Wibroe, SM Moghimi Maturitas 73 (1), 5-18, 2012 | 150 | 2012 |
SM MoghimiProfessor of Pharmaceutics and Nanomedicine; School of Pharmacy and Institute of Cellular Medicine在 ncl.ac.uk 的电子邮件经过验证
